Regen BioPharma Inc (RGBP)

[John Kent]

See this filing below going much lower ship is starting to take on water if company is already selling this low could be lights out here soon

Item 1.01 Entry into a Material Definitive Agreement



On November 15, 2018 David Koos ( the Chairman and CEO of Regen BioPharma, Inc.) , Regen BioPharma Inc., Bostonia Partners Inc., Sherman Family Trust, Dunhill Ross Partners Inc. and Bio-Technology Partners Business Trust collectively entered into an agreement to sell an aggregate of 23,733,334 shares of common stock, 667 shares of Series AA preferred stock, 534 shares of Series AAA Preferred Stock and 1,001,533 shares of Non-Voting Convertible Preferred Stock of Entest Group, Inc. to an unaffiliated third party (“Agreement”).

Of that aggregate, 8,000,000 shares of the common stock and 185,852 of the Non-Voting Convertible Preferred Stock of Entest Group, Inc. are being sold by Regen BioPharma, Inc. proceeds from the sale to be received by Regen Biopharma, Inc. are:

$48,000 from the sale of 8,000,000 shares of the common stock

$1,858.52 from the sale of the Non-Voting Convertible Preferred Stock

The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by Entest.



Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all rent prepaid by RGBP to Entest from the beginning of time to November 30, 2018 by transferring to RGBP 475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by Entest.

https://backend.otcmarkets.com/otcapi/company/financial-report/208788/content